Trials / Recruiting
RecruitingNCT07345715
Oral Melatonin Versus Nebulized Dexmedetomidine on Emergence Agitation in Children Undergoing Adenotonsillectomy
Comparison Between Oral Melatonin Versus Nebulized Dexmedetomidine on Emergence Agitation in Children Undergoing Adenotonsillectomy: A Prospective, Randomized Controlled Trial
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- Tanta University · Academic / Other
- Sex
- All
- Age
- 3 Years – 7 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to compare the efficacy of using oral Melatonin versus nebulized Dexmedetomidine in limitation of emergence agitation in children undergoing adenotonsillectomy.
Detailed description
Adenotonsillectomy is one of the most commonly performed surgical procedures in children with high incidence of emergence agitation about 80% and high degree of post operative pain. Oral midazolam, a short-acting benzodiazepine, is commonly used as a standard premedication in children due to its well-established anxiolytic, sedative, and amnestic effects. It works by enhancing GABAergic neurotransmission in the central nervous system, helping reduce anxiety and facilitating a smoother anesthetic induction and emergence. Dexmedetomidine is a centrally acting α-2 adrenergic agonist with sedative, hypnotic, analgesic, anxiolytic, anti-sialagogue, antinociceptive and sympatholytic action.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Normal saline | Participants will receive placebo nebulizer (3 ml of normal saline) without drug and 0.5 mg/kg of midazolam dissolved in Apple Juice. |
| DRUG | Oral melatonin syrup | Participants will receive placebo nebulizer (3 ml of normal saline) without drug and 0.2 mg/kg of oral melatonin syrup. |
| DRUG | Nebulized dexmedetomidine | Participants will receive placebo syrup (Apple Juice) and 2 µ/kg nebulized dexmedetomidine prepared in 0.9% normal saline to a final volume of 3ml. |
Timeline
- Start date
- 2025-07-01
- Primary completion
- 2027-07-01
- Completion
- 2027-07-01
- First posted
- 2026-01-16
- Last updated
- 2026-01-16
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07345715. Inclusion in this directory is not an endorsement.